Our work has focused on the study of paired breast cancer PDXs before and after the development of chemotherapy resistance to identify targetable, KRAS mutant–associated signaling mechanisms that promote tumor progression and alter the tumor immune microenvironment. The gene discussed is KRAS; the disease is breast carcinoma.